The invention relates to kinase peptides and antibodies, as well as nucleic
acids related to these peptides and antibodies. The present invention provides
kinase peptides, antibodies, and related nucleic acids. The present invention
also provides diagnostic and therapeutic compositions and methods using
these peptides, antibodies and nucleic acids.
USPTO Serial Number 60-682,115
In an embodiment, a microfluidic chip for protein analysis is disclosed
wherein the microfluidic chip comprises a substrate wherein the substrate
comprises a conductive material, a loading channel produced in the substrate
wherein a sample may be added to the microfluidic chip and a main channel
having a desired configuration wherein the main channel runs from the loading
reservoir to an outlet channel. In an embodiment, the microfluidic chip
comprises a plurality of side channels engaged to the main channel wherein
the side channel extends from the main channel to a well. In an embodiment,
the microfluidic chip comprises an at least one antibody in communication
with at least one well wherein each antibody is capable of binding to a
specified protein.
USPTO Serial Number 60-682,166
SPRING 2008
DFCI Impact Spring 2008 Nuclea Biomarkers Drives Study into the Molecular Pathology of Cancer
04/10/08
NUCLEA BIOMARKERS ANNOUNCES THAT IT HAS RECEIVED A U.S. PATENT ON "KINASE PEPTIDES AND ANTIBODIES"
7/15/07
NUCLEA BIOMARKERS RENEWS RESEARCH COLLABORATION WITH DANA FARBER CANCER INSTITUTE
06/05/06
Nuclea Biomarkers Announces it has Received a Notice of Allowance for U.S. Design Patent
08/10/05
Nuclea Biomarkers Establishes Research Collaboration with Dana Farber Cancer Institute
03/08/06 - Berkshire Economic Development Corporation
Biotech firm on its way
Nuclea Biomarkers, LLC is a biotechnology services company that has developed a novel technology platform to improve greatly the efficiency of drug discovery research.
Using the Company's extensive libraries of genetic, molecular, and outcomes data and data-mining services, research professionals in pharmaceutical and life sciences companies are able to focus time and money on the most promising paths for diagnosing and treating a broad range of diseases.
